IL125645A0 - Recombinant phages - Google Patents

Recombinant phages

Info

Publication number
IL125645A0
IL125645A0 IL12564597A IL12564597A IL125645A0 IL 125645 A0 IL125645 A0 IL 125645A0 IL 12564597 A IL12564597 A IL 12564597A IL 12564597 A IL12564597 A IL 12564597A IL 125645 A0 IL125645 A0 IL 125645A0
Authority
IL
Israel
Prior art keywords
bacteriophages
bacterial
component
infections
relates
Prior art date
Application number
IL12564597A
Other languages
English (en)
Original Assignee
Phagen Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phagen Ab filed Critical Phagen Ab
Publication of IL125645A0 publication Critical patent/IL125645A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12564597A 1996-02-06 1997-02-05 Recombinant phages IL125645A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9600434A SE506771C2 (sv) 1996-02-06 1996-02-06 Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
PCT/SE1997/000172 WO1997029185A1 (en) 1996-02-06 1997-02-05 Recombinant phages

Publications (1)

Publication Number Publication Date
IL125645A0 true IL125645A0 (en) 1999-04-11

Family

ID=20401289

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12564597A IL125645A0 (en) 1996-02-06 1997-02-05 Recombinant phages
IL125645A IL125645A (en) 1996-02-06 1998-08-03 Use of a modified bacteriophage in the manufacture of a medicament

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL125645A IL125645A (en) 1996-02-06 1998-08-03 Use of a modified bacteriophage in the manufacture of a medicament

Country Status (16)

Country Link
EP (1) EP0889955B1 (xx)
JP (1) JP4015195B2 (xx)
KR (1) KR100459638B1 (xx)
CN (1) CN1125174C (xx)
AT (1) ATE266091T1 (xx)
AU (1) AU712767B2 (xx)
CA (1) CA2244792A1 (xx)
DE (1) DE69728975T2 (xx)
ES (1) ES2221033T3 (xx)
HU (1) HUP9901242A3 (xx)
IL (2) IL125645A0 (xx)
NO (1) NO323359B1 (xx)
NZ (1) NZ331580A (xx)
RU (1) RU2215032C2 (xx)
SE (1) SE506771C2 (xx)
WO (1) WO1997029185A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006717A2 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
GB9908195D0 (en) 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
EP1187914B1 (en) 1999-06-14 2005-05-25 Genentech, Inc. A structured peptide scaffold for displaying turn libraries on phage
DE60113851T2 (de) * 2000-07-25 2006-07-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bakteriophage mit breitem wirtsspektrum
US6914123B2 (en) 2001-04-17 2005-07-05 Genentech, Inc. Hairpin peptides with a novel structural motif and methods relating thereto
KR20040036176A (ko) * 2002-10-23 2004-04-30 (주)엘피스바이오텍 단백질의 특이적 결합을 매개로 한 박테리오파아지의선택적 숙주감염을 이용한 단백질간의 상호작용을분석하는 방법
CN102296051B (zh) * 2011-03-07 2014-09-17 江苏省农业科学院 一种宽宿主谱鸡白痢沙门氏菌噬菌体及其应用
RU2503716C1 (ru) * 2012-09-27 2014-01-10 Федеральное бюджетное учреждение науки Государственный научный центр прикладной микробиологии и биотехнологии (ФБУН ГНЦ ПМБ) ВИДОСПЕЦИФИЧЕСКИЙ ВИРУЛЕНТНЫЙ ШТАММ БАКТЕРИОФАГА, ОБЛАДАЮЩИЙ ЛИТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ Staphylococcus aureus, ВКЛЮЧАЯ МУЛЬТИРЕЗИСТЕНТНЫЕ ШТАММЫ
GB201308745D0 (en) * 2013-05-15 2013-06-26 Imp Innovations Bacteriophage
CN106198523A (zh) * 2016-07-06 2016-12-07 哈尔滨贝贝凯尔科技发展有限公司 微量元素检测试纸及其制备方法
US20200271657A1 (en) 2017-10-04 2020-08-27 Opko Pharmaceuticals, Llc Articles and methods directed to personalized therapy of cancer
CN112739416B (zh) * 2018-12-27 2024-09-06 国立大学法人东海国立大学机构 宿主细菌特异性纳米粒子
CN109679981A (zh) * 2019-02-21 2019-04-26 武汉大学 一种甲酰基肽定向进化噬菌体及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
SE9304060D0 (sv) * 1993-12-06 1993-12-06 Bioinvent Int Ab Sätt att selektera specifika bakteriofager

Also Published As

Publication number Publication date
AU712767B2 (en) 1999-11-18
WO1997029185A1 (en) 1997-08-14
NO983456L (no) 1998-10-06
KR19990082041A (ko) 1999-11-15
EP0889955B1 (en) 2004-05-06
SE506771C2 (sv) 1998-02-09
CA2244792A1 (en) 1997-08-14
JP4015195B2 (ja) 2007-11-28
NO323359B1 (no) 2007-04-10
CN1125174C (zh) 2003-10-22
EP0889955A1 (en) 1999-01-13
AU1681797A (en) 1997-08-28
DE69728975D1 (de) 2004-06-09
DE69728975T2 (de) 2005-05-04
NO983456D0 (no) 1998-07-27
NZ331580A (en) 1999-09-29
ATE266091T1 (de) 2004-05-15
KR100459638B1 (ko) 2005-02-24
HUP9901242A2 (hu) 1999-07-28
RU2215032C2 (ru) 2003-10-27
JP2000505648A (ja) 2000-05-16
SE9600434L (sv) 1997-08-07
SE9600434D0 (sv) 1996-02-06
ES2221033T3 (es) 2004-12-16
HUP9901242A3 (en) 2000-03-28
CN1210558A (zh) 1999-03-10
IL125645A (en) 2006-08-20

Similar Documents

Publication Publication Date Title
IL125645A0 (en) Recombinant phages
IL141639A (en) Multicomponent vaccines
HK1021824A1 (en) Compositions and methods for treating infections using analogues of indolicidin
NO20006191L (no) Vaksine
AU2196592A (en) Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
WO2002007742A3 (en) Bacteriophage having multiple host range
TR200002437T2 (tr) B grubu streptococcus antijenleri.
ATE213507T1 (de) Methode zur bindung von material an das beta- amyloid-peptid
AU2197392A (en) Hepatitis C virus from C-100-3 and env/core regions
FR21C1005I2 (fr) Antigenes de streptococcus pyogenes et fragments d'adn correspondants
SG144692A1 (en) Antigenic proteins of shrimp white spot syndrome virus and uses thereof
DE69535855D1 (de) Calciumbindende rekombinante antikörper gegen protein c
EP2261253A3 (en) Antibodies directed to Clostridium difficile
WO2005023992A3 (en) Compositions and methods for inhibiting white spot syndrome virus (wssv) infection
FR2692282B1 (fr) Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications.
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
DE69938130D1 (de) Neue peptide
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
AU2548597A (en) Antibodies against avirulence/pathogenicity proteins of plant pathogens
WO2002077648A3 (en) Pathogenic and commensal vaccine antigens
WO2003060067A3 (en) P85-alpha nucleic acids, polypeptides and related methods
ATE325130T1 (de) Strukturelles peptid mit antigenischenen eigenschaften, antigenischen verbindungen und verwendungen im nachweis, vorbeugung und behandlung einer vhc-infektion
SE9600436D0 (sv) Vaccine against hantavirus
AU3346197A (en) Pharmaceutical composition, comprising complement proteins, for the treatment of helicobacter infections and a method for the preparation of the composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed